Xencor Inc. (Ticker: XNCR) is a clinical-stage biopharmaceutical company that focuses on discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases. Their innovative technology platform enables the creation of optimized antibodies with enhanced therapeutic potential.

Currently, the long-term trend of Xencor Inc.'s stock is messy, indicating a lack of clear direction or trend. This suggests that the stock price has been experiencing significant fluctuations without a consistent upward or downward movement. Additionally, the 200-day moving average, which is a commonly used indicator to assess the long-term trend, is still facing down. This implies that the average price of the stock over the past 200 days is declining. 

Traders and investors will closely monitor these technical indicators to determine if the stock can establish a more stable and positive trend in the future.